Thymosin Alpha-1 for Hepatitis B: A Randomized Trial Shows Benefits in Hard-to-Treat Patients
Thymosin alpha-1 improved virological and biochemical response rates in anti-HBe positive chronic hepatitis B patients, a subgroup that is particularly difficult to treat with standard therapies.
Quick Facts
What This Study Found
Thymosin alpha-1 improved virological (HBV DNA clearance) and biochemical (ALT normalization) responses in anti-HBe positive chronic hepatitis B, a treatment-resistant subgroup.
Key Numbers
How They Did This
Multicenter randomized controlled trial comparing thymosin alpha-1 to no treatment in anti-HBe, HBV-DNA-positive chronic hepatitis B patients. Six-month treatment course with follow-up monitoring of HBV DNA and liver enzymes.
Why This Research Matters
Anti-HBe positive hepatitis B has few effective treatments. A peptide immunotherapy that achieves meaningful response rates in this difficult subgroup addresses a significant unmet clinical need.
The Bigger Picture
Hepatitis B affects 300 million people worldwide. For the subset with anti-HBe positive disease, treatment options are limited. Thymosin alpha-1's immune-boosting approach offers a different mechanism from standard antivirals.
What This Study Doesn't Tell Us
Specific response rates and confidence intervals not detailed in abstract excerpt. Anti-HBe positive HBV is heterogeneous. Long-term durability of response not established in this study.
Questions This Raises
- ?Should thymosin alpha-1 be combined with nucleos(t)ide analogs for better HBV responses?
- ?What immune mechanisms mediate thymosin alpha-1's antiviral effect?
- ?Can thymosin alpha-1 achieve functional cure (HBsAg loss)?
Trust & Context
- Key Stat:
- Treatment-resistant subgroup Thymosin alpha-1 achieved virological and biochemical responses in anti-HBe positive hepatitis B — a subtype that resists standard treatments
- Evidence Grade:
- Moderate evidence from a multicenter RCT in a relevant and difficult-to-treat patient population.
- Study Age:
- Published in 2000. Thymosin alpha-1 is approved for hepatitis B treatment in some countries, often combined with other antivirals.
- Original Title:
- A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.
- Published In:
- Digestive diseases and sciences, 45(4), 690-6 (2000)
- Authors:
- Zavaglia, C, Severini, R, Tinelli, C, Franzone, J S, Airoldi, A, Tempini, S, Bettale, G, Ideo, G
- Database ID:
- RPEP-00637
Evidence Hierarchy
Frequently Asked Questions
Can thymosin alpha-1 treat hepatitis B?
Yes, this randomized trial showed it improved viral clearance and liver function in a particularly hard-to-treat type of chronic hepatitis B. It's approved for this use in some countries.
How does it work differently from antivirals?
Standard antivirals directly block virus replication. Thymosin alpha-1 boosts the immune system to fight the virus naturally. This immune approach may be why it works in patients resistant to direct antivirals.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00637APA
Zavaglia, C; Severini, R; Tinelli, C; Franzone, J S; Airoldi, A; Tempini, S; Bettale, G; Ideo, G. (2000). A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.. Digestive diseases and sciences, 45(4), 690-6.
MLA
Zavaglia, C, et al. "A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.." Digestive diseases and sciences, 2000.
RethinkPeptides
RethinkPeptides Research Database. "A randomized, controlled study of thymosin-alpha1 therapy in..." RPEP-00637. Retrieved from https://rethinkpeptides.com/research/zavaglia-2000-a-randomized-controlled-study
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.